May 21, 2013

Double Your Money in No Time Flat


Read the original article at Money Morning

If you’re looking to double your money, the biotech sector is one of the best hunting grounds that you’ll find.

So far this year, for instance, the iShares NASDAQ Biotechnology Index (NASDAQ: IBB) – an ETF that’s a great proxy for the sector – has zoomed 28.2%, more than double the 13.59% SPDR S&P 500 Index ETF (NYSEArca: SPY). The IBB gained 31% last year.

And a lot of individual biotech stocks have actually doubled, tripled or more – the Holy-Grail type of gains that high-tech investors crave.

But there’s a problem.

You see, not all biotech stocks are created equal.

To continue reading, please click here…

Read the original article at Money Morning

Double Your Money in No Time Flat


Read the original article at Money Morning

If you’re looking to double your money, the biotech sector is one of the best hunting grounds that you’ll find.

So far this year, for instance, the iShares NASDAQ Biotechnology Index (NASDAQ: IBB) – an ETF that’s a great proxy for the sector – has zoomed 28.2%, more than double the 13.59% SPDR S&P 500 Index ETF (NYSEArca: SPY). The IBB gained 31% last year.

And a lot of individual biotech stocks have actually doubled, tripled or more – the Holy-Grail type of gains that high-tech investors crave.

But there’s a problem.

You see, not all biotech stocks are created equal.

To continue reading, please click here…

Read the original article at Money Morning

Why This Stock (and Sector) Will Trounce All Others


Read the original article at Money Morning

Forget gold, forget oil, and forget the S&P 500.

If you want to make big money in the market today you have to look to biotech.

In fact, if you ignore this field, you’re going to miss some of the market’s biggest stock gains.

That’s because what happened earlier this week is going to become the norm.

On Monday, of the top 25 Nasdaq advancing stocks, 12 were straight-up biotech plays and another was a small-cap healthcare concern.

Their one-day gains ranged from 8% to 47%. Not bad for a day’s trade.

To continue reading, please click here…

Read the original article at Money Morning

Medical Miracle: Biotech Duo Is “Printing” New Organs


Read the original article at Money Morning

Imagine a future in which anyone needing a transplant could just create the needed tissue on their home printer.

That day hasn’t arrived yet … but it’s getting closer all the time.

A partnership between a global software firm and an early-stage biotech player is already promising to transform the field of medical transplants.

And for many patients, that day can’t get here soon enough.

To continue reading, please click here…

Read the original article at Money Morning

Why the Pentagon Wants to Use This Penny Stock to Cure the Flu


Read the original article at Money Morning

A tiny clinical-stage biotech firm is pioneering a ground-breaking new way to fight the flu.

Their process is so radical it has caught the eye of DARPA , the shadowy research and development arm of the Pentagon.

What makes their process so unique is that the company uses tobacco plants instead of eggs to produce the recombinant proteins that are the key to vaccines.

Its goal is to dramatically cut the time it takes to manufacture vaccines, which can take as long as nine months to put into production.

In fact, in a key test of the firm’s technology DARPA recently ordered 10 million doses of a vaccine candidate as part of a $21 million project.

By all accounts they came through with flying colors, delivering 10 million doses of the H1N1 influenza vaccine in just one month.

So who is this ground-breaking new vaccine company?

It’s a tiny Canadian-based firm called Medicago Inc. (OTC:MDCGF; TSX:MDG).

To continue reading, please click here…

Read the original article at Money Morning